Peptonic Medical (PMED) Q1 2026 earnings summary

Executive summary

• Achieved a significant turnaround post-restructuring, with a more focused and cost-efficient organization positioned for sustainable growth and improved profitability.

• Strategic focus on expanding the product portfolio in women's intimate health, with two new product launches under the VagiVital brand.

• Strong development in the Norwegian consumer market, now a significant part of e-commerce sales.

Financial highlights

• Net sales for Q1 2026 were 3,138 KSEK, down 17% year-over-year from 3,758 KSEK.

• Gross profit was 2,121 KSEK (2,165 KSEK last year), with a gross margin of 68% (up from 58%).

• Operating loss improved to -5,330 KSEK from -7,459 KSEK year-over-year.

• Earnings per share were -0.0005 SEK, compared to -0.001 SEK in Q1 2025.

• Cash flow from operations was -5,484 KSEK, with cash and bank balances at 628 KSEK as of March 31, 2026.

Outlook and guidance

• Focus remains on product innovation, sales growth, and brand building in the women's health segment.

• Anticipates capital inflow from upcoming warrants in June, which would further strengthen the financial position and support growth investments.